T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Clinical trials for T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for young patients with Hard-to-Treat T-Cell cancers
Disease control Recruiting nowThis early-phase trial tests whether adding the drug daratumumab after a stem cell transplant is safe for children, teens, and young adults with high-risk T-cell acute lymphoblastic leukemia or lymphoma. Participants first receive high-dose chemotherapy and total body irradiation…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated May 26, 2026 11:05 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. Doctors take a patient's (or their donor's) immune cells, add a special receptor that helps them recognize and attack cancer cells, and give them back. The goal is to see …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
Engineered immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment for people with T-cell leukemia or lymphoma that has come back or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), modify them in the lab to recognize and attack cancer cells carrying the CD7 prot…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Engineered immune cells take aim at hard-to-treat t-cell cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The treatment uses the patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CD7. The goal i…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 22, 2026 13:53 UTC